ScoreWhy is Orchid Pharma Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.62%
- Poor long term growth as Net Sales has grown by an annual rate of 12.91% and Operating profit at 15.64% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92
2
The company has declared Negative results for the last 5 consecutive quarters
- PAT(9M) At Rs 3.69 cr has Grown at -95.23%
- PBT LESS OI(Q) At Rs -10.65 cr has Fallen at -346.1% (vs previous 4Q average)
- ROCE(HY) Lowest at 4.28%
3
Stock is technically in a Mildly Bearish range
- The stocks MACD and KST technical factors are also Bearish
4
With ROCE of 2.3, it has a Very Expensive valuation with a 2.7 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -4.79%, its profits have fallen by -76.5%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Orchid Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Orchid Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Orchid Pharma
33.09%
-0.12
40.82%
Sensex
-11.61%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.46%
EBIT Growth (5y)
15.60%
EBIT to Interest (avg)
2.09
Debt to EBITDA (avg)
5.73
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.59
Tax Ratio
0.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.47%
ROCE (avg)
1.37%
ROE (avg)
4.82%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
325
Industry P/E
36
Price to Book Value
4.56
EV to EBIT
1377.03
EV to EBITDA
139.10
EV to Capital Employed
3.93
EV to Sales
5.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.94%
ROE (Latest)
0.71%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(Latest six months)
At Rs 672.50 cr has Grown at 34.32%
PAT(Q)
At Rs 3.22 cr has Grown at 40.8% (vs previous 4Q average
-9What is not working for the Company
PAT(9M)
At Rs 23.78 cr has Grown at -36.38%
ROCE(HY)
Lowest at 1.27%
DEBT-EQUITY RATIO(HY)
Highest at 0.28 times
NON-OPERATING INCOME(Q)
is 69.06 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Orchid Pharma
Profit After Tax (PAT) - Quarterly
At Rs 3.22 cr has Grown at 40.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 2.29 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 672.50 cr has Grown at 34.32%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Orchid Pharma
Debt-Equity Ratio - Half Yearly
Highest at 0.28 times and Grown
each half year in the last five half yearly periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income - Quarterly
is 69.06 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
